Clinical rationale for treatment of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin

Journal of Clinical Microbiology

Volumn 46, Issue 7, 2008, Pages 2471-

  Gqada, Zukile ^a   Marais, Ben ^a   Wasserman, Elizabeth ^a   Bamford, Colleen ^a   Orth, Heidi ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; FLUCLOXACILLIN; LEVOFLOXACIN; NAFCILLIN; OXACILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; BACTEREMIA; DRUG EFFICACY; DRUG EXPOSURE; DRUG SUBSTITUTION; ENDOCARDITIS; HUMAN; LETTER; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; TREATMENT RESPONSE; ADULT; ANTIBIOTIC RESISTANCE; BACTERIAL ENDOCARDITIS; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGY; NOTE; STAPHYLOCOCCUS INFECTION;

STAPHYLOCOCCUS AUREUS;

ADULT; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; ENDOCARDITIS, BACTERIAL; HUMANS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 49049110757     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00519-08     Document Type: Letter

References (8)

1. Alborn, W. E., Jr., N. E. Allen, and D. A. Preston. 1991. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob. Agents Chemother. 35:2282-2287.
2. Chang, F. Y., J. E. Peacock, Jr., D. M. Musher, P. Triplett, B. B. MacDonald, J. M. Mylotte, A. O'Donnell, M. M. Wagener, and V. L. Yu. 2003. Staphylococcus aureus bacteremia recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine 82:333-339.
3. Fowler, V. G., Jr., H. W. Boucher, and G. R. Corey. 2006. Daptomycin versus standard therapy for bacteraemia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665.
4. Hancock, R. E. W. 2005. Mechanisms of action of newer antibiotics for gram-positive pathogens. Lancet Infect. Dis. 5:209-218.
5. Lodise, T. P., Jr., P. S. McKinnon, D. P. Levine, and M. J. Rybak. 2007. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 51:3731-3733.
6. Moise, P. A., D. S. Smyth, N. El-Fawal, and D. A. Robinson. 2008. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother. 61:85-90.
7. Thorne, G. M., and J. Alder. 2002. Daptomycin: a novel lipopeptide antibiotic. Clin. Microbiol. Newsl. 24:33-40.
8. Sakoulas, G., W. Rose, M. J. Rybak, S. Pillai, J. Alder, R. C. Moellering, Jr., and G. M. Eliopoulos. 2008. Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J. Clin. Microbiol. 46:220-224.